Clinical Trials Search
Clinical Trial 20306
Cancer Type: Head & Neck
Study Type: Treatment
NCT#: NCT04119453
Phase: Phase II
Prinicipal Investigator: Jameel Muzaffar
Study Title
A Phase 2 Open-Label, Multicenter, Study to Evaluate the Efficacy and Safety of Rivoceranib in Subjects with Recurrent or Metastatic Adenoid Cystic Carcinoma of All Anatomic Sites of Origin
Summary
This is a Phase 2, multicenter, open-label, single-arm study of rivoceranib to evaluate its efficacy and safety in adult subjects with metastatic ACC of all anatomic sites of origin.
Objective
Primary Objective: To evaluate the efficacy of rivoceranib in subjects with recurrent or metastatic adenoid cystic adenocarcinoma (ACC) based on assessment of objective response rate (ORR). Secondary Objective: To further evaluate the efficacy in subjects with recurrent or metastatic ACC: Overall survival (OS), Disease control rate (DCR), Progression free survival (PFS) and Time to progression (TTP). To evaluate the safety of rivoceranib. Exploratory Objectives: To explore pharmacodynamics markers, to evaluate the pharmacokinetics (PK) of revoceranib. To evaluate quality of life measurements during treatment with rivoceranib.
Therapies
Medications
Rivoceranib ()
>
>
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.